Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
88 participants
INTERVENTIONAL
2020-05-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Telemedicine Qualifying Transition Between Tertiary and Primary Health Care in Stable Coronary Artery Disease Patients
NCT02489565
Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study
NCT02797158
Coronary Computed Tomography Angiography For Optimized Invasive Coronary examInation
NCT05218694
Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging
NCT03518437
Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
NCT02984891
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telemedicine FU
Telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Telemedicine FU
Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Office FU
Office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Office FU
Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Telemedicine FU
Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Office FU
Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 40 years
3. PCI with coronary artery stenting for ACS
4. Angiographic success PCI
Exclusion Criteria
2. Severe CHF (EF LV \<35% or functional class of heart failure III-IV NYHA)
3. Severe valvular heart disease or Prosthetic heart valves.
4. Severe forms of CKD (GFR\<30mL/min)
5. Planned staged revascularization during the next 12 months
6. Planned surgery within the next 12 months
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tomsk National Research Medical Center of the Russian Academy of Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ivan S Bessonov, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tyumen Cardiology Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science
Tyumen, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TeleFU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.